THOMAS, MCNERNEY & PARTNERS CLOSES $375 MILLION
LIFE SCIENCE & MEDICAL TECHNOLOGY FUND

Stamford, Minneapolis, San Francisco – September 6, 2006 - Thomas, McNerney & Partners, a health care venture capital firm that invests in life science and medical technology companies, today announced the close of its second fund, Thomas, McNerney & Partners II, L.P. with $375 million in limited partner commitments. Consistent with the firm’s inaugural $216 million fund raised in 2002, Thomas, McNerney & Partners II will focus on leading investments in biotechnology, pharmaceutical and medical device companies across all stages of development.

The fund will have the flexibility to invest in a broad range of companies including those at the start-up, pre-clinical and clinical stage, as well as in companies seeking capital for commercialization, asset acquisitions, restructuring and consolidation. The partnership will seek opportunities in which more that $5 million and up to $40 million may be invested over the life of the company and where the firm can actively participate as a lead investor.

“Thomas, McNerney & Partners II will employ the same successful strategy set forth in our inaugural fund,” said James Thomas, co-founder and partner. “The size of this fund will allow us to increase our capital commitment per company and to expand our overall investment reach while still enabling us to invest in a variety of opportunities, regardless of stage and sector.”

Thomas, McNerney & Partners is managed by a team of seven investment professionals. Members include partners, James Thomas, Pete McNerney, Karen Boezi, Alex Zisson, and Pratik Shah, Ph.D. and associates, Kathleen Tune and Christine Siu. With over 60 years of collective experience in health care venture capital and private equity, the team has a unique, multi-stage investment skill set developed through investing more than $600 million in 48 companies at all stages of development. Of these companies, 29 have become public companies or been acquired. Most recently, OsteoBiologics, Inc. was purchased by Smith & Nephew plc and Coley Pharmaceutical Group, Inc. had its initial public offering. Representative historical portfolio companies include: American Medical Systems Holdings, Inc., Cerus Corporation, Coulter Pharmaceutical, Inc., Epicor Medical, Inc., The Medicines Company, Transkaryotic Therapies, Inc. and Wright Medical Group, Inc.

The team has led or co-led over 90% of the investments in the Thomas, McNerney & Partners, L.P. portfolio and at least one of the firm’s partners serves on the board of each company in that fund. The partnership has offices in Connecticut, Minnesota and California, allowing it broad geographical reach and the ability to provide portfolio companies with local support as well as access to multiple networks.

“We are very pleased with the outcome of this fundraising effort,” noted Pete McNerney, co-founder and partner. “Many Fund I investors substantially increased their commitment to Thomas, McNerney & Partners II and several additional high quality investors became limited partners.”

About Thomas, McNerney & Partners
Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning-out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations. The firm is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. The firm has offices in Stamford, Minneapolis and San Francisco. For further information, please visit www.tm-partners.com.